🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 38 of 55

  1. Paclitaxel

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  2. Paclitaxel

    Cardiff Oncology

    Carcinosarcoma

    phase 2 small molecule active

    1 trial

  3. Paclitaxel

    ONCOLYTICS BIOTECH INC

    Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  4. Paclitaxel

    Jazz Pharmaceuticals Ireland Limited

    Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  5. Paclitaxel

    ONCOLYTICS BIOTECH INC

    Breast Cancer Metastatic

    phase 2 small molecule active

    1 trial

  6. Paclitaxel

    Takeda

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  7. Paclitaxel

    CNS Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  8. Paclitaxel

    Takeda

    Endometrial Neoplasms

    phase 2 small molecule completed

    1 trial

  9. Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Tislelizumab, Paclitaxel 6 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  10. Paclitaxel Kabi 6 mg/ml koncentrátum oldatos infúzióhoz, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, 68Ga-FAPI-46, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion, Epirubicin Eugia 2 mg/ml oplossing voor injectie, Cyclophosphamid beta 500 mg/ml Konzentrat zur Herstellung einer Injektions-/Infusionslösung

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  11. Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab

    The First People's Hospital of Lianyungang

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  12. Paclitaxel and TAK-228

    Takeda

    Metastatic Urothelial Cancer

    phase 2 other active

    1 trial

  13. Padcev 30 mg powder for concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion

    The George Institute

    locally advanced or metastatic penile squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  14. Padcev 30 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Padcev 20 mg powder for concentrate for solution for infusion

    Disc Medicine

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  15. Palbociclib 125Mg Tab

    United Therapeutics Europe Ltd

    ER+ Breast Cancer

    phase 2 small molecule active

    1 trial

  16. Palifosfamide Tris and Doxorubicin

    Alaunos Therapeutics

    Soft Tissue Sarcoma

    phase 2 small molecule active

    1 trial

  17. Pamorelin® LA 3,75 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension, RO7197597, ANASTROZOLE ACCORD 1 mg, comprimé pelliculé

    Partner Therapeutics Limited

    ER-positive/HER2-negative early breast cancer

    phase 2 small molecule active

    1 trial

  18. Pancreatoduodenectomy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 other active

    1 trial

  19. Panitumumab

    Takeda

    Squamous Cell Carcinoma of Head and Neck

    phase 2 small molecule completed

    1 trial

  20. Panitumumab

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Head and Neck Squamous Cancer

    phase 2 small molecule completed

    1 trial

  21. Panitumumab

    United Therapeutics Europe Ltd

    Metastatic Colon Adenocarcinoma

    phase 2 mab active

    1 trial

  22. Panitumumab + TAS-102

    Takeda

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  23. Panobinostat

    Zealand Pharma A/S

    Rhabdoid Tumor

    phase 2 small molecule terminated

    1 trial

  24. Panobinostat

    Novartis Pharmaceuticals

    Classical Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  25. Pantoprazole 40mg

    Zealand Pharma A/S

    Oncology

    phase 2 small molecule completed

    1 trial

  26. Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)

    CASI Pharmaceuticals

    Carcinoid Tumor

    phase 2 small molecule completed

    1 trial

  27. Panzem Nanocrystal Colloidal Dispersion (NCD)

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  28. Panzem® NCD

    CASI Pharmaceuticals

    Metastatic Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  29. Panzem® NCD

    CASI Pharmaceuticals

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  30. Parsaclisib

    Incyte

    Lymphoma

    phase 2 small molecule completed

    1 trial

  31. Part 1: VP-315 3 Day Dosing/Week

    Verrica Pharmaceuticals

    Basal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  32. Patritumab deruxtecan

    Daiichi Sankyo

    Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  33. Patritumab deruxtecan

    Daiichi Sankyo

    Locally Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  34. Patupilone

    Novartis Pharmaceuticals

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  35. Paxalisib

    KAZIA THERAPEUTICS LTD

    Childhood Cancer

    phase 2 small molecule active

    1 trial

  36. Pedmark® STS

    FENNEC PHARMACEUTICALS INC.

    Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  37. Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen

    The First People's Hospital of Lianyungang

    NK-T-Cell Lymphoma, Extranodal

    phase 2 small molecule active

    1 trial

  38. Pegvorhyaluronidase alfa

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  39. Pegylated Irinotecan

    Nektar Therapeutics UK Limited

    Recurrent Small Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  40. Pegylated Irinotecan

    Nektar Therapeutics UK Limited

    Stage IV Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule completed

    1 trial

  41. Pelareorep

    ONCOLYTICS BIOTECH INC

    Anatomic Stage IV Breast Cancer AJCC v8

    phase 2 mab active

    1 trial

  42. Pelareorep

    ONCOLYTICS BIOTECH INC

    Anal Cancer Metastatic

    phase 2 small molecule active

    1 trial

  43. Pemazyre 4.5 mg tablets

    The George Institute

    locally advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements

    phase 2 small molecule active

    1 trial

  44. Pemazyre 4.5 mg tablets

    Ningbo Cancer Hospital

    Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rearrangement or activating mutation, outside of the approved indications for any selective FGFR inhibitor in France

    phase 2 small molecule active

    1 trial

  45. Pemazyre 4.5 mg tablets, INCAGN02385, INCAGN02390, Retifanlimab (INCMGA00012)

    Incyte

    Endometrial cancer, Endometrial cancer

    phase 2 small molecule active

    1 trial

  46. Pembrolizumab

    Syndax Pharmaceuticals

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  47. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Advanced Non-Small Cell Lung Cancer

    phase 2 mab completed

    1 trial

  48. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Melanoma

    phase 2 mab completed

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.